Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer
Linda Coate(University Health Network), Frances A. Shepherd(University Health Network), Natasha B. Leighl(Princess Margaret Cancer Centre), Katherine Barrett(University Health Network), A. Sun(University of Toronto), Andrea Bezjak(Princess Margaret Cancer Centre), Adrian G. Sacher(Princess Margaret Cancer Centre), Marc de Perrot(University Health Network), Gail Darling(University Health Network), Byoung Chul Cho(Yonsei University), Anthony Brade(Princess Margaret Cancer Centre), Ronald L. Burkes(Mount Sinai Hospital), Shaf Keshavjee(University Health Network), Geoffrey Liu(Princess Margaret Cancer Centre), Andrew Pierre(University Health Network), Ronald Feld(University Health Network), Christine Massey(University of Vermont), Andrew Hope(University of Toronto)
Cited by 56
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k